Legal/Regulatory Five things for pharma marketers to know: Monday, July 11, 2016

Five things for pharma marketers to know: Monday, July 11, 2016

Purdue Pharma reportedly knew about OxyContin trafficking; Amgen's Repatha approved for monthly dosing option; Clinton proposes new healthcare measures

Corporate Five things for pharma marketers to know: Friday, June 17, 2016

Five things for pharma marketers to know: Friday, June 17, 2016

Hillary Clinton receives more donations from pharma than republicans; biotech reps have highest salaries; NICE recommends Yervoy-Opdivo combo

Commercial Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.

Commercial Five things for pharma marketers to know: Wednesday, May 25, 2016

Five things for pharma marketers to know: Wednesday, May 25, 2016

Antidepressants are often used to treat conditions other than depression; the FDA delays decision on Duchenne drug; Lilly and Pfizer develop new painkiller

Pipeline Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Therapeutic Focus Top 20 autoimmune products, 2015

Top 20 autoimmune products, 2015

AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.

Agency 2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Commercial Five things for pharma marketers to know: Friday, April 29, 2016

Five things for pharma marketers to know: Friday, April 29, 2016

Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations

Commercial Rolling with the Punches as Marketing Evolves

Rolling with the Punches as Marketing Evolves

Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.

Commercial Five things for pharma marketers to know: Monday, April 11, 2016

Five things for pharma marketers to know: Monday, April 11, 2016

Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review